With Pro Ultra Omega-3, Bayer Dives Deeper Into Consumer Health Competition
This article was originally published in The Tan Sheet
Bayer HealthCare’s Consumer Care division launches the Pro Ultra brand with the product’s recent debut in the US, leveraging the firm’s presence in the heart health product space.
You may also be interested in...
A survey of doctors and pharmacists reports 83% of their patients with abnormally high cholesterol express interest in using omega-3 supplements. But the survey sponsored by Rx omega-3 firm Amarin also raises questions about health care professionals’ knowledge of FDA regulation of supplement products.
Pharma firms’ introduction and wide promotion of Rx drugs containing EPA or DHA acids and aimed at improving cardiovascular health were expected to boost omega-3 supplement sales, but negative research results reported over the past year could diminish consumers’ regard for the nutrients’ benefits.
CHPA members’ feedback on RRAs indicate that “time and resources saved by FDA do not translate to time saved by the manufacturer.” CRN suggests FDA “clearly identify the purpose of the RRA in its initial request and limit requested documents to only those directly related to the purpose of the RRA.”